PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways

Xu,Xiaohui; Cui,Yushang; Cao,Lei; Zhang,Ye; Yin,Yan; Hu,Xue

doi:10.3892/etm.2017.4218

PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways

Authors:
- Xiaohui Xu
- Yushang Cui
- Lei Cao
- Ye Zhang
- Yan Yin
- Xue Hu
View Affiliations

Affiliations: Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing 100730, P.R. China
Published online on: March 10, 2017 https://doi.org/10.3892/etm.2017.4218
Pages: 1993-1999

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of PCs that encodes a neural apoptosis-regulated convertase 1. However, the precise role of PCSK9 in lung cancer cell apoptosis has remained elusive. In the present study, A549 human lung adenocarcinoma cells were transfected with PCSK9 small interfering (si)RNA to investigate the underlying mechanisms of apoptosis. The results indicated that PCSK9 siRNA exhibited anti‑tumor activity by inducing apoptosis as determined by a Cell Counting Kit‑8 and Hoechst staining analysis. In addition, PCSK9 siRNA significantly increased apoptosis of A549 cells in part via activation of caspase‑3 and downregulation of the anti‑apoptotic proteins survivin and X‑linked inhibitor of apoptosis protein. Moreover, the results demonstrated that perturbations in the mitochondrial membrane were associated with the deregulation of the Bax/Bcl-2 ratio, which led to the release of cytochrome c after PCSK9 siRNA transfection. In addition, PCSK9 siRNA also induced endoplasmic reticulum stress (ERS) by increasing the levels of 78 kDa glucose‑regulated protein (GRP78), GRP94, phosphorylated protein kinase R‑like ER kinase and phosphorylated eukaryotic initiation factor 2α. Therefore, these results demonstrated that PCSK9 siRNA may exert its anti-tumor activity through inducing mitochondrial dysfunction and ERS-associated cell death in A549 cells.

View Figures

View References

1	Liang R, Chen TX, Wang ZQ, Jin KW, Zhang LY, Yan QN, Zhang HH and Wang WP: A respective analysis of the clinicopathological characteristics of large cell carcinoma of lung. Exp Ther Med. 9:197–202. 2015.PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Mrazek AA and Chao C: Surviving cutaneous melanoma: A clinical review of follow-up practices, surveillance, and management of recurrence. Surg Clin North Am. 94:989–1002, vii-viii. 2014. View Article : Google Scholar : PubMed/NCBI
4	Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR and Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res. 11:3974–3986. 2005. View Article : Google Scholar : PubMed/NCBI
5	Horton JD, Cohen JC and Hobbs HH: Molecular biology of PCSK9: Its role in LDL metabolism. Trends Biochem Sci. 32:71–77. 2007. View Article : Google Scholar : PubMed/NCBI
6	Park SW, Moon YA and Horton JD: Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 279:50630–50638. 2004. View Article : Google Scholar : PubMed/NCBI
7	Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M and Allard D: NARC-1/PCSK9 and its natu-ral mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 279:48865–48875. 2004. View Article : Google Scholar : PubMed/NCBI
8	Peterson AS, Fong LG and Young SG: PCSK9 function and physiology. J Lipid Res. 49:1595–1599. 2008. View Article : Google Scholar : PubMed/NCBI
9	Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 34:154–156. 2003. View Article : Google Scholar : PubMed/NCBI
10	Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK and Hobbs HH: Low LDL holesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 37:161–165. 2005. View Article : Google Scholar : PubMed/NCBI
11	Cohen JC, Boerwinkle E, Mosley TH Jr and Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 354:1264–1272. 2006. View Article : Google Scholar : PubMed/NCBI
12	Seidah NG and Prat A: The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 11:367–383. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lan H, Pang L, Smith MM, Levitan D, Ding W, Liu L, Shan L, Shah VV, Laverty M, Arreaza G, et al: Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J Cell Physiol. 224:273–281. 2010.PubMed/NCBI
14	Ranheim T, Mattingsdal M, Lindvall JM, Holla OL, Berge KE, Kulseth MA and Leren TP: Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. J Cell Physiol. 217:459–467. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamellin J, Tremblay M, Jacques H, Jin W, Davignon J, et al: Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 48:646–654. 2008. View Article : Google Scholar : PubMed/NCBI
16	Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, Prat A, Seidah NG, Chretien M and Scott FW: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 584:701–706. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sun XW, Essalmani R, Day R, Khatib AM, Seidah NG and Prat A: Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia. 14:1122–1131. 2012. View Article : Google Scholar : PubMed/NCBI
18	Faitova J, Krekac D, Hrstka R and Vojtesek B: Endoplasmic reticulum stress and apoptosis. Cell Mol Biol Lett. 11:488–505. 2006. View Article : Google Scholar : PubMed/NCBI
19	Chiang LW, Grenier JM, Ettwiller L, Jenkins LP, Ficenec D, Martin J, Jin F, DiStefano PS and Wood A: An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis. Proc Natl Acad Sci USA. 98:2814–2819. 2001. View Article : Google Scholar : PubMed/NCBI
20	LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
21	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
22	Pettersson F, Dalgleish AG, Bissonnette RP and Colston KW: Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer. 87:555–561. 2002. View Article : Google Scholar : PubMed/NCBI
23	Dufey E, Sepulveda D, Rojas-Rivera D and Hetz C: Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 1. An overview. Am J Physiol Cell Physiol. 307:C582–C594. 2014. View Article : Google Scholar : PubMed/NCBI
24	Yuan T, Luo BL, Wei TH, Zhang L, He BM and Niu RC: Salubrinal protects against cigarette smoke extract-induced HBEpC apoptosis likely via regulating the activity of PERK-eIF2α signaling pathway. Arch Med Res. 43:522–529. 2012. View Article : Google Scholar : PubMed/NCBI
25	Stockwell SR, Platt G, Barrie SE, Zoumpoulidou G, Te Poele RH, Aherne GW, Wilson SC, Sheldrake P, McDonald E, Venet M, et al: Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 7:e285682012. View Article : Google Scholar : PubMed/NCBI
26	Duan Z, Zhao J, Fan X, Tang C, Liang L, Nie X, Liu J, Wu Q and Xu G: The PERK-eIF2α signaling pathway is involved in TCDD-induced ER stress in PC12 cells. Neurotoxicology. 44:149–159. 2014. View Article : Google Scholar : PubMed/NCBI
27	Jiang Q, Li F, Shi K, Wu P, An J, Yang Y and Xu C: Involvement of p38 in signal switching from autophagy to apoptosis via the PERK/eIF2α/ATF4 axis in selenite-treated NB4 cells. Cell Death Dis. 5:e12702014. View Article : Google Scholar : PubMed/NCBI
28	Liu CY, Schroder M and Kaufman RJ: Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem. 275:24881–24885. 2000. View Article : Google Scholar : PubMed/NCBI
29	Szegezdi E, Logue SE, Gorman AM and Samali A: Mediators of endoplas-mic reticulum stress-induced apoptosis. EMBO Rep. 7:880–885. 2006. View Article : Google Scholar : PubMed/NCBI